Janssen Pharmaceutical K.K.
129
0
5
109
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
10.9%
14 terminated/withdrawn out of 129 trials
88.6%
+2.1% vs industry average
39%
50 trials in Phase 3/4
45%
49 of 109 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (129)
A Study of Macitentan in Japanese Pediatric Participants With Pulmonary Arterial Hypertension
Role: lead
A Study of Bedaquiline Administered as Part of a Treatment Regimen With Clarithromycin and Ethambutol in Adult Patients With Treatment-refractory Mycobacterium Avium Complex-lung Disease (MAC-LD)
Role: lead
A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma
Role: lead
A Study of AAV5-hRKp.RPGR for the Treatment of Japanese Participants With X-linked Retinitis Pigmentosa
Role: lead
A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer
Role: lead
A Study of Teclistamab in Japanese Participants With Relapsed or Refractory Multiple Myeloma
Role: lead
A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
Role: lead
A Study of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
Role: lead
A Registry Study of Palmoplantar Pustulosis (PPP) Treatment Patterns, Disease Burden and Treatment Outcomes in Japan
Role: lead
A Registry Study to Observe Clinical Outcomes of Participants With High-risk Metastatic Hormone-naïve Prostate Cancer in Japan
Role: lead
A Study of JNJ-64407564 in Japanese Participants With Relapsed or Refractory Multiple Myeloma
Role: lead
A Study of JNJ-75220795 in Japanese Participants
Role: lead
A Study of Guselkumab in Participants With Systemic Sclerosis
Role: lead
A Study of Ibrutinib in Combination With Rituximab, in Japanese Participants With Waldenstrom's Macroglobulinemia (WM)
Role: lead
A Study of Adenovirus Serotype 26.Respiratory Syncytial Virus.Pre-Fusion F (Ad26.RSV.preF)-Based Vaccine for Prevention of Respiratory Syncytial Virus (RSV) Mediated- Lower Respiratory Tract Disease (LRTD) in Japanese Participants
Role: lead
A Study of Ustekinumab in Participants With Active Polymyositis and Dermatomyositis Who Have Not Adequately Responded to One or More Standard-of-care Treatments
Role: lead
A Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant Depression
Role: lead
A Study of Ustekinumab in Participants With Takayasu Arteritis (TAK)
Role: lead
A Study of JNJ-67953964 in Healthy Japanese Adult Male Participants
Role: lead
A Study of JNJ-40411813 in Healthy Japanese Male Participants
Role: lead